.Johnson & Johnson’s deprioritization of its infectious disease pipeline has asserted an additional target in the form of its own dengue virus vaccination mosnodenvir.Mosnodenvir is created to block out communications in between two dengue infection proteins. The vaccine endured J&J’s selection in 2014 to merge its own infectious ailment and vaccine functions, which observed the likes of a late-stage breathing syncytial infection program dropped from the Large Pharma’s pipe and an E. coli vaccine liquidated to Sanofi.Mosnodenvir has possessed a tough time in the medical clinic, along with J&J terminating one trial due to the effect of COVID-19 on enrollment and pausing recruitment in one more study in 2022.
Yet the loyalty to mosnodenvir looked to repay in October 2023, when the vaccine was actually revealed to induce a dose-dependent antiviral effect on the detectability as well as beginning of dengue virus serotype 3 in a phase 2 trial. That data reduce does not seem to have sufficed to conserve mosnodenvir for long, along with the Big Pharma announcing this morning that it is terminating a follow-up phase 2 field research. The selection is associated with a “key reprioritization of the business’s pandemic illness R&D profile,” incorporated J&J, which worried that no protection concerns had been identified.” Johnson & Johnson will remain to assist the aggression versus dengue by sharing research study leads with the health care neighborhood later on,” the pharma pointed out in the launch.J&J had been investing in dengue for over a decade, including launching a Gps Center for Global Health And Wellness Discovery at the Duke-NUS Medical Institution in Singapore in 2022.
The center has been actually focused on speeding up early-stage discovery research to “take care of the developing challenge of flaviviruses” like dengue as well as Zika.